Targeting therapy using chemotherapy-resistant pancreatic cancer stem cells
Project/Area Number |
23592007
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Kobe University |
Principal Investigator |
SHIMIZU Kazuya 神戸大学, 保健学研究科, 研究員 (50335353)
|
Co-Investigator(Kenkyū-buntansha) |
HORI Yuichi 神戸大学, 保健学研究科, 教授 (80248004)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
Keywords | 膵臓がん / がん幹細胞 / 癌幹細胞 / 膵臓癌 / 微小環境 |
Research Abstract |
Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. tabine-resistant pancreatic ductal adenocarcinoma patients. By use of in vitro co-culture system with stromal cells, we established a novel pancreatic tumor-initiating cell line. The cell line required its direct interaction with stromal cells for its in vitro clonogenic growth and passaging. Their direct interaction induced basal lamina-like extracellular matrix formation that maintained colony formation. The cell line expressed CD133 protein, which expression level changed autonomously and by culture conditions. These results demonstrated that there were novel pancreatic tumor-initiating cells that required direct interactions with stromal cells for their in vitro cultivation in gemcitabine-resistant pancreatic ductal adenocarcinoma. This cell line would help to develop novel therapies that enhance effects of gemcitabine or novel anti-cancer drugs.
|
Report
(4 results)
Research Products
(19 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] 肝胆膵2013
Author(s)
堀裕一
Total Pages
734
Publisher
アークメディア
Related Report
-